Literature DB >> 8694508

Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies.

F Podo1, A Ferretti, A Knijn, P Zhang, C Ramoni, B Barletta, C Pini, S Baccarini, S Pulciani.   

Abstract

Although evidence supports constitutive activation of phosphatidylcholine specific phospholipase C (PC-plc) in rastransformed fibroblasts, no studies have been devoted to measure the basal activity levels of this enzyme, its molecular characteristics and subcellular localization. This paper reports for the first time measurements of the activity of different enzymes responsible for PC hydrolysis (PC-plc; phospholipases A2 (pla2) and A1 (pla1)) in homogenates of murine NIH-3T3 fibroblasts (3T3) and their transformants obtained by human H-ras transfection (3T3ras). To this end, 31P NMR analyses were carried out on total cell homogenates, incubated in the presence of mixed diheptanoylphosphatidylcholine: sphingomyelin (DHPC:SM) unilamellar vesicles (SLUV), in which DHPC acts as a suitable substrate for water-soluble lipolytic enzymes. The basal PC-plc activity levels (0.66 +/- 0.14 and 0.38 +/- 0.10 nmol/10(6) cells.hour in 3T3 and 3T3ras fibroblasts, respectively),were substantially higher (over 30-50x) than those reported in the literature for normal mammalian cells (dog heart myocytes). Moreover the PC-plc activity was about 15-30 times lower than the overall PC deacylation activity in both clones. The use of high titer polyclonal antibodies, raised in a rabbit against bacterial PC-plc, allowed identification of one cross-reactive mammalian PC-plc component (M(r) 66 kD) in cell lysates of both 3T3 and 3T3ras fibroblasts, and detection, by indirect immunofluorescence, of its subcellular localization. In control 3T3 fibroblasts (in the late log-phase of growth) the enzyme was exclusively located in the cytosol, while in H-ras transformed cells it was massively exposed on the external side of the membrane. This new finding strongly suggests that the oncogenic product p2Iras is able to induce (or mediate) translocation of PC-plc across the plasma membrane of ras transformed cells, with possible implications not only on cell biochemistry (enhancement of PC-plc activity, and consequent production of intra- and extracellular PCho and accumulation of neutral lipids) but also on cell-cell interaction mechanisms which facilitate tumour invasion and metastasis of oncogene-transformed cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694508

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.

Authors:  Egidio Iorio; Alessandro Ricci; Marina Bagnoli; Maria Elena Pisanu; Giancarlo Castellano; Massimo Di Vito; Elisa Venturini; Kristine Glunde; Zaver M Bhujwalla; Delia Mezzanzanica; Silvana Canevari; Franca Podo
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  In vivo detection of phospholipase C by enzyme-activated near-infrared probes.

Authors:  Theresa M Mawn; Anatoliy V Popov; Nancy J Beardsley; Klara Stefflova; Matthew Milkevitch; Gang Zheng; E James Delikatny
Journal:  Bioconjug Chem       Date:  2011-11-29       Impact factor: 4.774

Review 3.  MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Authors:  Kristine Glunde; Lu Jiang; Siver A Moestue; Ingrid S Gribbestad
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

4.  A quantitative continuous enzyme assay of intramolecularly quenched fluorogenic phospholipase substrates for molecular imaging.

Authors:  Theresa M Mawn; Anatoliy V Popov; E James Delikatny
Journal:  Anal Biochem       Date:  2011-12-09       Impact factor: 3.365

5.  Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.

Authors:  Laura Fantuzzi; Francesca Spadaro; Cristina Purificato; Serena Cecchetti; Franca Podo; Filippo Belardelli; Sandra Gessani; Carlo Ramoni
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

6.  Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells.

Authors:  Sridhar Nimmagadda; Kristine Glunde; Martin G Pomper; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

7.  Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells.

Authors:  Laura Abalsamo; Francesca Spadaro; Giuseppina Bozzuto; Luisa Paris; Serena Cecchetti; Luana Lugini; Egidio Iorio; Agnese Molinari; Carlo Ramoni; Franca Podo
Journal:  Breast Cancer Res       Date:  2012-03-19       Impact factor: 6.466

8.  Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.

Authors:  Luisa Paris; Serena Cecchetti; Francesca Spadaro; Laura Abalsamo; Luana Lugini; Maria Elena Pisanu; Egidio Iorio; Pier Giorgio Natali; Carlo Ramoni; Franca Podo
Journal:  Breast Cancer Res       Date:  2010-05-12       Impact factor: 6.466

9.  Human prostate cell lines from normal and tumourigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C.

Authors:  M Rumsby; J Schmitt; M Sharrard; G Rodrigues; M Stower; N Maitland
Journal:  Br J Cancer       Date:  2011-01-25       Impact factor: 7.640

10.  Nuclear phosphoinositide-specific phospholipase C β1 controls cytoplasmic CCL2 mRNA levels in HIV-1 gp120-stimulated primary human macrophages.

Authors:  Francesca Spadaro; Serena Cecchetti; Cristina Purificato; Michela Sabbatucci; Franca Podo; Carlo Ramoni; Sandra Gessani; Laura Fantuzzi
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.